Related Experiment Video
Updated: May 1, 2026

Generation of Multivirus-specific T Cells to Prevent/treat Viral Infections after Allogeneic Hematopoietic Stem Cell Transplant
Published on: May 27, 2011
Development of adenovirus-based oncolytic virus to induce EBV lytic reactivation
Sun Hee Lee1, Hyeji Byun1, Donghyun Seo1
1Healthcare Convergence Educational Group for Infectious Disease Management, Vessel-Organ Interaction Research Center, Research Institute of Pharmaceutical Science, College of Pharmacy, Kyungpook National University, 80 Daehak-ro, Buk-gu, Daegu, 702-701, Republic of Korea.
Background:
Oncolytic viruses (OVs) selectively replicate in and lyse tumor cells. Epstein-Barr virus-associated gastric carcinoma (EBVaGC), representing ~ 10% of gastric cancers globally, remains a therapeutic challenge. We developed Ad-TBZ, a novel oncolytic adenovirus engineered to selectively target EBVaGC by inducing EBV lytic reactivation.
Methods:
Ad-TBZ was constructed by inserting an hTERT promoter (hTERTp)-driven E1A/IRES-E1B cassette and a CMV promoter (CMVp)-driven BZLF1 gene into the adenoviral genome. We evaluated Ad-TBZ replication, cytotoxicity, and EBV lytic reactivation in EBVaGC cell lines (SNU719, NCC24, YCCEL1, AGS-EBV, MKN1-EBV), EBV-negative cells, and normal fibroblasts (CCD-986sk). In vivo efficacy was assessed using SNU719 and MKN1-EBV xenograft mouse models. Combination effects with platinum-based drugs and ganciclovir were also investigated.
Results:
Ad-TBZ selectively replicated in EBVaGC cells and demonstrated cell line-specific cytotoxic effects while sparing normal cells. It significantly upregulated EBV lytic genes (BRLF1, BMRF1, BGLF4, BXLF1, BALF4, BLLF1), increased viral genome copies, and induced cell line-specific late apoptosis. In vivo, Ad-TBZ effectively suppressed tumor growth in both xenograft models without systemic toxicity. Sequential treatment with oxaliplatin showed modest synergistic effects at specific concentrations in limited conditions, while most combination approaches showed no significant synergistic effects. These findings indicate Ad-TBZ functions optimally as a monotherapy.
Conclusions:
Ad-TBZ demonstrates potent and selective antitumor activity against EBVaGC through hTERTp-mediated selective replication and BZLF1-induced EBV lytic reactivation. These findings support Ad-TBZ as a promising novel monotherapeutic strategy for EBVaGC.
Insights
A novel oncolytic adenovirus, Ad-TBZ, shows potent antitumor activity against Epstein-Barr virus-associated gastric cancer (EBVaGC). This engineered virus selectively targets and destroys EBVaGC cells, supporting its use as a monotherapy.
Area of Science:
- Oncolytic virology
- Cancer gene therapy
- Gastroenterology
Background:
- Epstein-Barr virus-associated gastric carcinoma (EBVaGC) accounts for ~10% of gastric cancers and presents therapeutic challenges.
- Oncolytic viruses (OVs) are engineered to selectively replicate in and lyse tumor cells.
Purpose of the Study:
- To develop and evaluate Ad-TBZ, a novel oncolytic adenovirus engineered for selective targeting of EBVaGC.
- To investigate Ad-TBZ's ability to induce Epstein-Barr virus (EBV) lytic reactivation in tumor cells.
Main Methods:
- Ad-TBZ was constructed with an hTERT promoter (hTERTp)-driven E1A/IRES-E1B cassette and a CMV promoter (CMVp)-driven BZLF1 gene.
- Replication, cytotoxicity, and EBV lytic reactivation were assessed in EBVaGC cell lines, EBV-negative cells, and normal fibroblasts.
- In vivo efficacy was evaluated in xenograft mouse models, with combination studies against platinum-based drugs and ganciclovir.
Main Results:
- Ad-TBZ demonstrated selective replication and cytotoxicity in EBVaGC cells, sparing normal cells.
- Significant upregulation of EBV lytic genes and increased viral genome copies were observed, leading to late apoptosis.
- Ad-TBZ effectively suppressed tumor growth in vivo without systemic toxicity, indicating optimal performance as a monotherapy.
Conclusions:
- Ad-TBZ exhibits potent and selective antitumor activity against EBVaGC via hTERTp-mediated replication and BZLF1-induced EBV lytic reactivation.
- These findings support Ad-TBZ as a promising novel monotherapeutic strategy for EBVaGC.
More Related Videos
Related Concept Videos
Retrovirus Life Cycles
Cross-reactivity
Mechanisms of Retrovirus-induced Cancers
Rous Sarcoma Virus (RSV) and Cancer
RSV is a retrovirus that contains two copies of a plus-strand RNA genome. Its genome consists of four main open...
Arboviral Encephalitis
Cytomegalovirus Disease

